Description
The skeptic raised concerns about MT1/MT2 receptor downregulation with chronic melatonin therapy, but this wasn’t resolved. Understanding dose-response relationships and receptor tolerance is critical for determining therapeutic windows and dosing regimens.
Source: Debate session sess_sda-2026-04-01-gap-v2-ee5a5023 (Analysis: sda-2026-04-01-gap-v2-ee5a5023)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:37.408345+00:00”, “resolution_summary”: “Partially addressed by hypothesis h-SDA-2026-04-26-gap-pubmed-20260411-090734-1be1b913-02-age-stratified-dosing-protocol-reflecting-endoge-16e7a70f57: Age-Stratified Dosing Protocol Reflecting Endogenous Decline. Additional debate or paper support is still needed.”, “match_counts”: {“hypothesis_matches”: 5, “debate_matches”: 0, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-SDA-2026-04-26-gap-pubmed-20260411-090734-1be1b913-02-age-stratified-dosing-protocol-reflecting-endoge-16e7a70f57”, “title”: “Age-Stratified Dosing Protocol Reflecting Endogenous Decline”, “score”: 0.382, “reason”: “6 token overlaps; entity overlap: mt1, mt2”, “analysis_id”: “SDA-2026-04-26-gap-pubmed-20260411-090734-1be1b913”, “target_gene”: “AANAT; ASMT; MT1/MT2”, “target_pathway”: null, “disease”: null, “composite_score”: 0.665, “confidence_score”: 0.428, “status”: “proposed”, “pubmed_evidence_ids”: [“12591118”, “12639921”, “15804509”, “29395258”, “29512439”]}, {“id”: “h-SDA-2026-04-26-gap-pubmed-20260411-090734-1be1b913-06-pulsatile-low-dose-protocol-to-prevent-receptor–1c14e5f647”, “title”: “Pulsatile Low-Dose Protocol to Prevent Receptor Desensitization”, “score”: 0.374, “reason”: “6 token overlaps; entity overlap: mt1, mt2”, “analysis_id”: “SDA-2026-04-26-gap-pubmed-20260411-090734-1be1b913”, “target_gene”: “MT1/MT2 receptors; GRK2/3; β-arrestin”, “target_pathway”: null, “disease”: null, “composite_score”: 0.405, “confidence_score”: 0.328, “status”: “proposed”, “pubmed_evidence_ids”: [“12882323”, “14507903”, “14997320”, “29395258”, “29512439”]}, {“id”: “h-SDA-2026-04-26-gap-pubmed-20260411-090734-1be1b913-03-circadian-phase-anchored-low-dose-melatonin-for–5f18bdd5f0”, “title”: “Circadian-Phase Anchored Low-Dose Melatonin for Prevention”, “score”: 0.371, “reason”: “6 token overlaps; entity overlap: mt1, mt2”, “analysis_id”: “SDA-2026-04-26-gap-pubmed-20260411-090734-1be1b913”, “target_gene”: “MT1/MT2 melatonin receptors; CLOCK/BMAL1”, “target_pathway”: null, “disease”: null, “composite_score”: 0.5850000000000001, “confidence_score”: 0.428, “status”: “proposed”, “pubmed_evidence_ids”: [“24136970”, “29395258”, “29425573”, “29512439”, “30793004”]}, {“id”: “h-SDA-2026-04-26-gap-pubmed-20260411-081101-dfe3eacb-07-mt1-receptor-activation-at-low-doses-synchronize-6b050bb98a”, “title”: “MT1 Receptor Activation at Low Doses Synchronizes Suprachiasmatic Nucleus and Reduces Neurodegeneration Progression”, “score”: 0.34, “reason”: “4 token overlaps; entity overlap: mt1, mt2”, “analysis_id”: “SDA-2026-04-26-gap-pubmed-20260411-081101-dfe3eacb”, “target_gene”: “MTNR1A (MT1), MTNR1B (MT2), PER1/PER2 clock genes, SOD2”, “target_pathway”: null, “disease”: null, “composite_score”: 0.405, “confidence_score”: 0.328, “status”: “proposed”, “pubmed_evidence_ids”: [“10384874”, “26254826”, “28795820”, “29032267”, “29392374”]}, {“id”: “h-SDA-2026-04-26-gap-pubmed-20260411-090734-1be1b913-01-ultra-low-physiological-replacement-dosing-for-l-8979704328”, “title”: “Ultra-Low Physiological Replacement Dosing for Long-Term Prevention”, “score”: 0.234, “reason”: “5 token overlaps; entity overlap: mt1”, “analysis_id”: “SDA-2026-04-26-gap-pubmed-20260411-090734-1be1b913”, “target_gene”: “MT1/ERK1/2 (MAPK1/3); Nrf2 (NFEL2L2); BACE1”, “target_pathway”: null, “disease”: null, “composite_score”: 0.735, “confidence_score”: 0.575, “status”: “proposed”, “pubmed_evidence_ids”: [“12882323”, “21480859”, “29395258”, “29512439”, “30793004”]}], “debate_matches”: [], “paper_matches”: []}